The EMEA Guideline on First-in-Human Clinical Trials and Its Impact on Pharmaceutical Development
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
On March 13, 2006, TGN1412, a monoclonal antibody, was administered to humans for the first time. Severe, lifethreatening toxicities ensued. The science behind these adverse events and the immediate responses to this event have been described in another article (Horvath and Milton 2009). The TeGenero incident was a wake-up call to the pharmaceutical industry, the clinical trials community, and the regulatory agencies. The incident was investigated thoroughly by several different groups, including the Expert Group on Phase One Clinical Trials (chaired by Professor Gordon Duff), the Royal Statistical Society, and the Early Stage Clinical Trial Taskforce. Each of these groups issued reports that summarized the causes of the adverse events and proposed ways that such adverse events could be avoided in future first-in-human (FIH) studies (Expert Group on Phase One Clinical Trials 2006; Medicines and Healthcare Products Regulatory Agency [MHRA] 2006; Early Stage Clinical Trial Taskforce 2007; Senn et al. 2007; Royal Statistical Society 2007). At the same time as these reports were being created, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) was working on creating a guideline on strategies to identify and mitigate risks for FIH clinical trials with investigational medicinal products.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Horvath, C. J., & Milton, M. N. (2009) · Toxicologic Pathology · doi:10.1177/0192623309332986 · Cited by 87 · cited 2×
“The topic of calculating the safe starting dose for pharmaceuticals in general, and TGN1412 in particular, has been discussed by Horvath and Milton (2009).”
BackgroundSelf-citation
Cited by
Horvath, C. J., & Milton, M. N. (2009) · Toxicologic Pathology · doi:10.1177/0192623309332986 · Cited by 87
Self-citationSafety of biologics, lessons learnt from TGN1412
Stebbings, R., Poole, S., & Thorpe, R. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.002 · Cited by 70
Implications of the BIA‐102474‐101 study for review of first‐into‐human clinical trials
Eddleston, M., Cohen, A. F., & Webb, D. J. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12920 · Cited by 66
Suh, H. Y., Peck, C., Yu, K.-S., & Lee, H. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s121520 · Cited by 51
First-in-Human Clinical Trials — What We Can Learn from Tragic Failures
Bonini, S., & Rasi, G. (2016) · New England Journal of Medicine · doi:10.1056/nejme1609006 · Cited by 17
Metadata
- Authors
- Milton, M. N., & Horvath, C. J.
- Venue
- Toxicologic Pathology
- Publisher
- SAGE Publications
- Published
- 2009-02-26
- Volume
- 37
- Issue
- 3
- Pages
- 363-371
- ISSN
- 0192-6233 (ISSN-L)
- 1533-1601
- OpenAlex
- W2105040789
- Cited by
- 63
- References
- 1
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The EMEA Guideline on First-in-Human Clinical Trials and Its Impact on Pharmaceutical Development. https://app.cochat.ai/papers/10.1177/0192623309332997
- The paper
- Milton, M. N., & Horvath, C. J. (2009). The EMEA Guideline on First-in-Human Clinical Trials and Its Impact on Pharmaceutical Development. Toxicologic Pathology. https://doi.org/10.1177/0192623309332997
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.